YUNNAN BAIYAO GROUP CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.33 CNY | 0.00% |
|
-2.43% | +12.57% |
| Apr. 26 | Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 24 | Yunnan Baiyao Group Co.,Ltd. Approves Cash Dividend for the Year 2023 | CI |
ETFs positioned on Yunnan Baiyao Group Co.,Ltd
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.68% | 2 M€ | -16.59% | - | |
| 1.32% | 2 M€ | -14.14% | ||
| 1.18% | 4 M€ | -2.96% | ||
| 0.13% | 35 M€ | -5.85% | - | |
| 0.11% | 3 M€ | -0.84% | - | |
| 0.10% | 4 M€ | -11.56% | ||
| 0.05% | 11 M€ | +1.79% | ||
| 0.01% | 4 M€ | -4.41% | - | |
| 0.01% | 441 M€ | +4.60% | - | |
| 0.01% | 2,808 M€ | +5.90% | - | |
| 0.01% | 149 M€ | +2.17% | - | |
| 0.01% | 117 M€ | +1.11% | - | |
| 0.00% | 31 M€ | +3.50% | - | |
| 0.00% | 7 M€ | +1.95% | - | |
| 0.00% | 34 M€ | +2.14% | - | |
| 0.00% | 147 M€ | +4.88% | - | |
| 0.00% | 34 M€ | +6.71% | - | |
| 0.00% | 389 M€ | +6.83% | - | |
| 0.00% | 39 M€ | +3.67% | - | |
| 0.00% | 302 M€ | +3.80% | - |
Yunnan Baiyao Group Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical products. The group proposes primarily traditional medicine products, phytobiological products, body care products, antibiotics and anti-inflammatory.
China accounts for 98.9% of net sales.
Sector
Pharmaceuticals
Calendar
2024-08-28
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
55.33
CNY
Average target price
62.1
CNY
Spread / Average Target
+12.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.57% | 13.62B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 000538 Stock
- Funds and ETFs Yunnan Baiyao Group Co.,Ltd
